Trial Profile

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
Indications Hodgkin's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Feb 2023 Planned End Date changed from 29 Oct 2022 to 28 Feb 2025.
30 Oct 2021 Planned End Date changed to 29 Oct 2022.
06 Nov 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com